+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Osteoarthritis - Pipeline Review, H2 2020

  • ID: 5146857
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 384 pages
  • Global Markets Direct

FEATURED COMPANIES

  • 4P-Pharma SAS
  • Axsome Therapeutics Inc
  • Eli Lilly and Co
  • Link Health Group
  • Orbsen Therapeutics Ltd
  • Seikagaku Corp
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Pipeline Review, H2 2020, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape.

Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews the key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 8, 23, 21, 1, 1, 56, 13 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 2, 8 and 7 molecules, respectively.

Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 4P-Pharma SAS
  • Axsome Therapeutics Inc
  • Eli Lilly and Co
  • Link Health Group
  • Orbsen Therapeutics Ltd
  • Seikagaku Corp
  • MORE
Introduction
  • Osteoarthritis - Overview
  • Osteoarthritis - Therapeutics Development
Osteoarthritis - Therapeutics Assessment

Osteoarthritis - Companies Involved in Therapeutics Development

Osteoarthritis - Drug Profiles

Osteoarthritis - Dormant Projects
  • Osteoarthritis - Discontinued Products
  • Osteoarthritis - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Osteoarthritis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Osteoarthritis - Pipeline by 4P-Pharma SAS, H2 2020
  • Osteoarthritis - Pipeline by Abiogen Pharma SpA, H2 2020
  • Osteoarthritis - Pipeline by Ablynx NV, H2 2020
  • Osteoarthritis - Pipeline by Aclaris Therapeutics Inc, H2 2020
  • Osteoarthritis - Pipeline by Adare Pharmaceuticals Inc, H2 2020
  • Osteoarthritis - Dormant Projects, H2 2020
  • Osteoarthritis - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Osteoarthritis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • 4P-Pharma SAS
  • Abiogen Pharma SpA
  • Ablynx NV
  • Aclaris Therapeutics Inc
  • Adare Pharmaceuticals Inc
  • Akaal Pharma Pty Ltd
  • AKL Research and Development Ltd
  • Algomedix Inc
  • Amgen Inc
  • Amplicore Inc
  • Amzell BV
  • Arthrogen BV
  • AskAt Inc
  • Asta Pharmaceuticals Co Ltd
  • Atlanthera
  • Aurealis Pharma AG
  • Axsome Therapeutics Inc
  • Bioiberica SAU
  • Bioorg3.14 LLC
  • BioStem Technologies Inc
  • Bone Therapeutics SA
  • BRIM Biotechnology Inc
  • CAR-T (Shanghai) Biotechnology Co Ltd
  • CarthroniX Inc
  • Cells for Cells SA
  • CellTex Therapeutics Corp
  • Cellular Biomedicine Group Inc
  • Chondrogenix Ltd
  • Chugai Pharmaceutical Co Ltd
  • Cocoon Biotech, Inc.
  • Corestem Inc
  • Cynata Therapeutics Ltd
  • Cytonics Corp
  • Daewoong Pharmaceutical Co Ltd
  • DNX Biopharmaceuticals Inc
  • Dongkook Pharmaceutical Co Ltd
  • Eli Lilly and Co
  • Ensol Biosciences Inc
  • Eternity Bioscience Inc
  • Evgen Pharma Plc
  • Flexion Therapeutics Inc
  • Galapagos NV
  • GeneFrontier Corp
  • Genequine Biotherapeutics GmbH
  • General Regeneratives Shanghai Ltd
  • Gwoxi Stem Cell Applied Technology Co Ltd
  • Haplnscience Inc
  • Histogen Inc
  • HSRx Group
  • Inception Therapeutics Inc
  • InKemia IUCT Group SA
  • International Stem Cell Corp
  • Kaken Pharmaceutical Co Ltd
  • Kang Stem Biotech Co Ltd
  • Kolon TissueGene Inc
  • Kukje Pharmaceutical Industry Co Ltd
  • Levolta Pharmaceuticals Inc
  • LG Chem Ltd
  • Link Health Group
  • Lubris Biopharma
  • Luye Pharma Group Ltd
  • MDimune Inc
  • Medicrinia Co Ltd
  • MediPost Co Ltd
  • Medivir AB
  • Meluha Life Sciences Sdn Bhd
  • Merck KGaA
  • Meridigen Biotech Co Ltd
  • Mesoblast Ltd
  • MetrioPharm AG
  • Mor Research Applications Ltd
  • Nanode Therapeutics Inc
  • NeuroBo Pharmaceuticals Inc
  • New York R&D Center for Translational Medicine and Therapeutics Inc
  • Nordic Bioscience AS
  • Novartis AG
  • Orbsen Therapeutics Ltd
  • OrthoTrophix Inc
  • Paradigm Biopharmaceuticals Ltd
  • Peptinov SAS
  • Personalized Stem Cells Inc
  • Pfizer Inc
  • Philogen SpA
  • PhytoHealth Corp
  • Plakous Therapeutics Inc
  • Progenitor Therapeutics Ltd
  • ProteoThera Inc
  • Regeneus Ltd
  • Regenosine Inc
  • Regulaxis SAS
  • Ribomic Inc
  • Rottapharm Biotech Srl
  • Samumed LLC
  • Sclnow Biotechnology Co Ltd
  • Seikagaku Corp
  • Serene LLC
  • Shionogi & Co Ltd
  • SL Bigen Inc
  • Steminent Biotherapeutics Inc
  • Stempeutics Research Pvt Ltd
  • Synartro AB
  • Synerkine Pharma BV
  • Synokem Pharmaceuticals Ltd
  • Taiwan Bio Therapeutics Co Ltd
  • Traverse Biosciences Inc
  • Unicocell Biomed Co Ltd
  • Unity Biotechnology Inc
  • WEX Pharmaceuticals Inc
  • WNT Scientific LLC
  • Xalud Therapeutics Inc
  • Xintela AB
  • Yooyoung Pharm Co Ltd
  • Zimmer Biomet Holdings Inc
Note: Product cover images may vary from those shown
Adroll
adroll